首页> 美国卫生研究院文献>The Journal of Molecular Diagnostics : JMD >Evaluation of 13q14 Status in Patients with Chronic Lymphocytic Leukemia Using Single Nucleotide Polymorphism-Based Techniques
【2h】

Evaluation of 13q14 Status in Patients with Chronic Lymphocytic Leukemia Using Single Nucleotide Polymorphism-Based Techniques

机译:基于单核苷酸多态性的技术评估慢性淋巴细胞白血病患者13q14状态

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Deletions of chromosome 13q14 are common in chronic lymphocytic leukemia and other cancers, demonstrating the importance of this region in tumorigenesis. We report the use of two single-nucleotide polymorphism (SNP)-based techniques to determine 13q loss of heterozygosity (LOH) status in 15 patients with CLL: (i) digital SNP (dSNP), where analysis of heterozygous SNPs detects allelic imbalances, and (ii) DNA sequencing, where LOH is identified by comparison of allelic peak heights in normal and neoplastic cells. The SNP-based techniques were compared with established molecular techniques, fluorescence in situ hybridization and multiplex ligation-dependent probe amplification, to determine their utility and relative sensitivity. dSNP proved to be the most sensitive technique, identifying 13q14 LOH in 11 of 13 (85%) patients (95% CI: 55%, 98%) without the need for neoplastic cell enrichment. Three cases showed evidence of LOH by dSNP that was not apparent by other techniques. In 8 of 13 (62%) cases, partial or interstitial patterns of LOH were observed by dSNP. Our findings demonstrate that dSNP represents a useful, sensitive technique for the analysis of chromosomal aberrations that result in LOH. It may have applications for the analysis of other malignancies that are difficult to assess by conventional molecular techniques.
机译:染色体13q14的缺失在慢性淋巴细胞性白血病和其他癌症中很常见,这表明该区域在肿瘤发生中的重要性。我们报告使用两种基于单核苷酸多态性(SNP)的技术来确定15名CLL患者的13q杂合性(LOH)状态丧失:(i)数字SNP(dSNP),其中杂合SNP的分析检测到等位基因失衡, (ii)DNA测序,其中LOH是通过比较正常细胞和肿瘤细胞中的等位基因峰高来鉴定的。将基于SNP的技术与已建立的分子技术,荧光原位杂交和多重连接依赖探针扩增进行比较,以确定其效用和相对灵敏度。 dSNP被证明是最灵敏的技术,无需赘生性细胞富集即可在13名患者中的11名(85%)(95%CI:55%,98%)中鉴定出13q14 LOH。 3例病例显示出dSNP引起的LOH证据,而其他技术则不明显。 13例中有8例(62%),通过dSNP观察到LOH的部分或间隙模式。我们的发现表明,dSNP代表了一种有用的,灵敏的技术,可用于分析导致LOH的染色体畸变。它可以用于分析其他常规分子技术难以评估的恶性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号